Data for drugs available through low-cost prescription drug programs are available through pharmacy benefit manager and claims data

Table 2 Proportion of patients using selected oral hypoglycemic agent (OHA) by chain

Ingredient	MEPS	Chain14	Chain11	Chain1	Chain10	Chain4	Chain2	Chain5	Chain13
Chlorpropamide *	0.2	0.04	0.01	0	0.02	0	0	0	0.03
Glimepiride *	9.1	17.1	19.4	18.8	18.0	17.8	22.4	16.5	19.9
Glipizide *	14.5	17.6	20.3	23.8	20.4	20.3	18.6	12.9	19.6
Glyburide *	10.7	4.3	5.9	3.7	4.9	4.2	2.6	3.4	4.6
Metformin *	51.0	69.1	72.8	53.3	72.8	62.4	66.2	80.0	59.9
Acarbose	0.1	0.4	0.3	0.9	0.4	0.2	0.2	0.2	0.4
Glimepiride/Pioglitazone	0.3	0.2	0.26	1.1	0.2	0.1	0.8	0.1	0.2
Glimepiride/Rosiglitazone	0.5	0.4	0.17	0.4	0.4	0.6	0.4	0.2	0.5
Glipizide/Metformin	0.1	0.6	0.56	0.9	0.5	0.8	0.6	0.2	0.7
Glyburide/Metformin	4.1	4.0	3.8	6.3	1.5	2.6	3.6	1.2	4.1
Pioglitazone	11.1	17.5	15.4	27.1	15.9	19.2	22.2	14.9	25.8
Pioglitazone/Metformin	1.8	3.3	2.5	1.1	2.6	3.0	2.4	1.6	3.6
Repaglinde	0.8	0.8	0.5	0.9	0.6	0.9	0.8	0.1	1.0
Rosiglitazone	0.5	3.0	2.3	6.8	3.1	3.0	3.4	2.3	5.6
Rosiglitazone/Metformin	0.6	1.4	1.1	2.3	1.6	1.5	1.8	1.2	2.0
Sitagliptin	4.0	10.8	9.0	12.2	9.4	12.7	12.2	8.8	14.3
Sitagliptin/Metformin	1.1	4.9	4.3	2.8	4.5	6.7	6.1	4.5	5.3
Low-cost OHA		85.3	89.0	78.5	89.0	83.2	83.4	90.0	79.0
Non-low-cost OHA		55.3	33.8	52.1	34.4	43.4	43.7	29.3	52.2